Vanda Pharmaceuticals | VNDA - Pre Utilidad Fiscal





Pre Utilidad Fiscal Cambio Fecha
Acadia Pharmaceuticals USD 26.32M 18.28M 2025-12
Agios Pharmaceuticals USD -109.06M 5.62M 2025-12
Akebia Therapeutics USD -11.24M 12.39M 2025-12
Alnylam Pharmaceuticals USD 161.14M 77.83M 2025-12
Anika Therapeutics USD 764K 3M 2025-12
Arrowhead Research USD 28.27M 7.85M 2025-12
AstraZeneca USD 3.24B 117M 2025-09
Bristol-Myers Squibb USD 3.11B 1.34B 2025-09
Eli Lilly USD 7.23B 456M 2025-09
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
Esperion Therapeutics USD 63.67M 95M 2025-12
Halozyme Therapeutics USD 218.96M 14.02M 2025-09
Heron Therapeutics USD -2.95M 14.54M 2025-12
Insmed USD -326.93M 41.77M 2025-12
J&J USD 4.97B 2.53B 2025-12
Lexicon Pharmaceuticals USD -12.77M 16.02M 2025-09
Ligand Pharmaceuticals USD 141.14M 102M 2025-09
Merck USD 6.74B 22M 2025-09
Minerva Neurosciences USD 22.51M 30.74M 2024-09
Moderna USD -187M 631M 2025-09
Novartis USD 5.17B 637M 2025-09
Pfizer USD 3.33B 290M 2025-09
PTC Therapeutics USD -139.08M 116.01M 2025-12
Puma Biotechnology USD 20.61M 24.76M 2024-09
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Sanofi EUR -1.16B 5.5B 2025-12
Takeda JPY 133.86B 105.69B 2025-12
Teva Pharmaceutical Industries USD 91M 555M 2025-12
Ultragenyx Pharmaceutical USD -128M 51.54M 2025-12
Vanda Pharmaceuticals USD -22.92M 16.68M 2024-12
Veracyte USD 40.63M 21.74M 2025-12